Trial Profile

A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 12 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telisotuzumab adizutecan (Primary)
Indications Adenocarcinoma; Advanced breast cancer; Biliary cancer; Head and neck cancer; HER2 negative breast cancer; Liver cancer; Male breast cancer; Oesophageal cancer; Pancreatic ductal carcinoma; Solid tumours; Squamous cell cancer; Triple negative breast cancer
Focus Therapeutic Use
Sponsors AbbVie

Most Recent Events

29 Oct 2024 Planned number of patients changed from 220 to 260.
29 May 2024 Trial design ( As of 19 January 2024, 24 patients have been enrolled) is discussed in an abstract published at 60th Annual Meeting of the American Society of Clinical Oncology
20 Mar 2024 Planned End Date changed from 20 Jul 2026 to 1 Jul 2026.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com